Efficacy and Safety Evaluation of Anti-Caries Varnish


Advantage Silver Dental Arrest

Status and phase

Active, not recruiting
Phase 2


Dental Caries in Children


Drug: Test varnish
Drug: Placebo

Study type


Funder types




Details and patient eligibility


The purpose of the study is to determine the efficacy & safety of Advantage Anti-Caries Varnish for primary prevention. The objectives are: 1) To determine if Advantage Anti-Caries Varnish (test varnish) is superior to an active control varnish (5% Sodium Fluoride, no Povidone-Iodine) in the prevention of caries lesions in the primary dentition. Specifically, prevention of caries lesions in primary teeth that either are sound, have only d1 (white spots) lesions or unerupted at baseline; and 2) To document the safety of the test varnish.

Full description

This is a single center randomized, double-blind, placebo-controlled, parallel-group trial. The treatment group will be exposed at baseline and once every three to four months after baseline for a maximum period of 24 months. The control group will be exposed to the control varnish in the same manner. 254 subjects will be enrolled. Half will be randomized to each arm. Subjects will be 10-20 mo of age and in good health. Children attending Maternal and Child Health (MCH) Immunization and Well Child programs in Pohnpei State will be enrolled. Primary Outcome Variables: 1) Surface-level dental caries lesions (d2-4mfs) at 24 months post baseline; 2) Presence/Absence of dental caries lesions (d2-4mfs >0) at 12 months post baseline. Secondary Outcome Variable: Adverse Events


274 patients




10 to 20 months old


Accepts Healthy Volunteers

Inclusion criteria

  • The subject's parent or legal guardian must provide signed and dated informed consent (parent permission form).
  • The subject's parent or legal guardian of the subject must be willing and able to comply with study requirements.
  • The subject is a 10-20 months at the time of enrollment.
  • The subject must be in good general health as evidenced by parent report.
  • The subject will have at least 1 erupted tooth that is either sound or has only a d1 (white spots) lesion.

Exclusion criteria

  • Previous treatment with fluoride varnish
  • Known allergy to iodine
  • Diagnosis of thyroid disease
  • Chronic, prophylactic use of antibiotics
  • Treatment with another investigational drug or intervention within 30 days preceding the Baseline Visit.
  • Visible cavities (d2-4)
  • Presence of intraoral pathology that would make assessment of post treatment soft tissue ulcerations or inflammation impossible (child could be enrolled if problem is treated and lesions cleared)
  • Parent anticipates the child will move from Pohnpei during the next 2 years.

Trial design

Primary purpose




Interventional model

Parallel Assignment


Quadruple Blind

274 participants in 2 patient groups

Test Varnish
Experimental group
Anti-Caries Varnish. The active ingredients are 10% (w/v) Povidone-Iodine and 5% (w/v) Sodium Fluoride CAS.
Drug: Test varnish
Control Varnish
Active Comparator group
Control Varnish. 5% (w/v) Sodium Fluoride .
Drug: Placebo

Trial contacts and locations



Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems